BPZE1 has been developed with more than $18 million in funding.

• ILiAD Biotechnologies has raised $8.5 million to conduct business development, R&D and clinical research activities.
• $10 million of European Union funding supported early BPZE1 research and a clinical study.

Since licensing BPZE1 in December 2013, ILiAD has made significant progress furthering vaccine development, including:

• Demonstration of 99.9% reduction in B. pertussis nasopharyngeal colonization vs. controls in a non-human primate study
• Completion of a Phase 1b (high dose) clinical study at the Karolinska Hospital in Stockholm, Sweden
• Manufacturing process development to formulate a more stable and viable vaccine
• Synthesis, characterization and preclinical experiments for several modified BPZE1 strains
• Issuance by the US and European Patent and Trademark offices of BPZE1 vaccine patents with broad claims

ILiAD Biotechnologies is a privately held company represented by the Investment Banking firm of Walter Greenblatt & Associates (WGA). Qualified investors interested in participating in company financing should contact WGA.

Walter Greenblatt & Associates, Member FINRA, SIPC, is a life-science focused investment bank working with early stage companies around the world to raise the initial rounds of capital they need to advance their therapeutics, devices, diagnostics, healthcare IT or pharmaceutical services. www.wgreenblatt.com